Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571727 · ClinicalTrials.gov registry record · Phase 2
Long-Term Treatment With rhIGF-1 in GHIS
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00571727 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 92 participants.
The verdict
NCT00571727, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).
Interventions
- DRUG mecasermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 1991-05-20 |
| Est. Completion | 2011-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571727
The ClinicalTrials.gov registry entry for NCT00571727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mecasermin is the first listed.
NCT00571727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571727 about?
NCT00571727 is a clinical study titled "Long-Term Treatment With rhIGF-1 in GHIS". The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).
What is the current status of trial NCT00571727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 1991-05-20. Estimated completion is 2011-12-15.
What interventions are being tested in trial NCT00571727?
The interventions under investigation include: mecasermin (DRUG).
Who is sponsoring clinical trial NCT00571727?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.